Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
  2. Parexel launches integrated FPS model to drive delivery of clinical research partnerships
  3. Medable unveils telemedicine solution only for clinical trials
  4. Broader inclusion criteria to double eligible cancer patients for clinical trials, finds study
  5. Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus

Latest Content

August’s top news stories

Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients; and MyoKardia has commenced dosing of patients in a Phase I trial of small molecule MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM). Clinicaltrialsarena.com wraps up the key headlines from August 2019.

Soliris – Treatment for PNH, aHUS, gMG, and NMOSD

Soliris (eculizumab) is a drug indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

Latest News

Close
Close
Close

Go Top